CTLA4 and melanoma: While CTLA-4 inhibitors can elicit adverse reactions such as exhaustion and gastrointestinal disturbances, blocking CTLA-4 in melanoma therapy has been associated with severe Immune-Related Adverse Events(AE), including autoimmune complications in visceral organs such as the colon, liver, and endocrine glands (28).